MENAFRIVAC

This brand name is authorized in Nigeria.

Active ingredients

The drug MENAFRIVAC contains a combination of these active pharmaceutical ingredients (APIs):

`1`	Meningococcal serogroup A polysaccharide vaccine UNII `1I86B47NY4` - NEISSERIA MENINGITIDIS GROUP A CAPSULAR POLYSACCHARIDE ANTIGEN
	Read more about Meningococcal serogroup A polysaccharide vaccine
`2`	Tetanus toxoid UNII `K3W1N8YP13` - CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)
	Read more about Tetanus toxoid

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A6-100060	Powder for injection	Meningococcal A Conjugate Vaccine 5 mcg INJ_PWD 5 mcg/0.5 mL 0.5 mL x 50's (in vial) + diluent (in ampoule)	Freeze-dried powder for injection in vial + diluent in ampoule. The diluent is a white slightly opaque homogeneous suspension presented in a 5 mL ampoule	20/10/2022

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J07AH10		J Antiinfectives for systemic use → J07 Vaccines → J07A Bacterial vaccines → J07AH Meningococcal vaccines
Discover more medicines within J07AH10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A6-100060

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.